Biocryst Pharmaceuticals (BCRX) Free Cash Flow: 2009-2024
Historic Free Cash Flow for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to -$53.1 million.
- Biocryst Pharmaceuticals' Free Cash Flow fell 35.25% to -$18.9 million in Q4 2015 from the same period last year, while for Dec 2015 it was -$18.2 million, marking a year-over-year increase of 52.82%. This contributed to the annual value of -$53.1 million for FY2024, which is 45.39% up from last year.
- As of FY2024, Biocryst Pharmaceuticals' Free Cash Flow stood at -$53.1 million, which was up 45.39% from -$97.3 million recorded in FY2023.
- Biocryst Pharmaceuticals' Free Cash Flow's 5-year high stood at -$53.1 million during FY2024, with a 5-year trough of -$163.2 million in FY2022.
- Moreover, its 3-year median value for Free Cash Flow was -$97.3 million (2023), whereas its average is -$104.6 million.
- As far as peak fluctuations go, Biocryst Pharmaceuticals' Free Cash Flow plummeted by 50.81% in 2020, and later surged by 45.39% in 2024.
- Over the past 5 years, Biocryst Pharmaceuticals' Free Cash Flow (Yearly) stood at -$135.6 million in 2020, then dropped by 6.58% to -$144.5 million in 2021, then fell by 12.91% to -$163.2 million in 2022, then spiked by 40.37% to -$97.3 million in 2023, then surged by 45.39% to -$53.1 million in 2024.